Literature DB >> 2802567

Pharmacokinetics of amikacin in hematologic malignancies.

S Kaojarern1, S Maoleekoonpairoj, V Atichartakarn.   

Abstract

The pharmacokinetics of amikacin in 10 patients with hematologic malignancies and 1 patient with aplastic anemia were investigated. At an administered dose of 7 mg/kg of body weight, a volume of distribution of 0.4 liters/kg, an elimination half-life of 3.0 h, and a total body clearance of 2.1 ml/min per kg, amikacin achieved a peak level in blood of 21 micrograms/ml. Results of the study revealed that there was a marked increase in volume of distribution of amikacin in these patients compared with normal.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802567      PMCID: PMC172668          DOI: 10.1128/AAC.33.8.1406

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Clinical pharmacology of amikacin and kanamycin.

Authors:  W M Kirby; J T Clarke; R D Libke; C Regamey
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

3.  The pharmacokinetics of amikacin in children.

Authors:  B Vogelstein; A Kowarski; P S Lietman
Journal:  J Pediatr       Date:  1977-08       Impact factor: 4.406

4.  Aminoglycoside volume of distribution in hematology-oncology patients.

Authors:  R P Manny; P R Hutson
Journal:  Clin Pharm       Date:  1986-08

5.  Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic.

Authors:  H Lode; K Grunert; P Koeppe; H Langmaack
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

6.  Comparative pharmacokinetics of amikacin and kanamycin.

Authors:  J T Clarke; R D Libke; C Regamey; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1974-06       Impact factor: 6.875

7.  Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia.

Authors:  E T Anderson; L S Young; W L Hewitt
Journal:  Am J Med       Date:  1976-10       Impact factor: 4.965

8.  Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function.

Authors:  D Höffler; P Koeppe; H G Demers
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

9.  Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis.

Authors:  P Noone; T M Parsons; J R Pattison; R C Slack; D Garfield-Davies; K Hughes
Journal:  Br Med J       Date:  1974-03-16

10.  Amikacin serum concentrations: prediction of levels and dosage guidelines.

Authors:  F A Sarubbi; J H Hull
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

View more
  8 in total

1.  Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.

Authors:  M Tod; O Lortholary; D Seytre; R Semaoun; B Uzzan; L Guillevin; P Casassus; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 2.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients.

Authors:  S Chang; R C Li; L S Chan; S Y Wong; M Zhu; A T Chan; K Raymond
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

4.  Gentamicin volume of distribution in critically ill septic patients.

Authors:  C Triginer; I Izquierdo; R Fernández; J Rello; J Torrent; S Benito; A Net
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

5.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Once daily antibiotic regimen in paediatric oncology.

Authors:  E Bouffet; C Fuhrmann; D Frappaz; D Couillioud; V Artiges; C Charra; D Bouhour; M Brunat Mentigny
Journal:  Arch Dis Child       Date:  1994-06       Impact factor: 3.791

7.  Relative pharmacokinetics of three amikacin brands in onco-hemotologic pediatric patients experiencing febrile neutropeina.

Authors:  Muhammad Jamshaid; Samia Yousuf; Nadeem Irfan Bukhari; Amir Ali Rizvi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

8.  Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy.

Authors:  R L Davis; D Lehmann; C A Stidley; J Neidhart
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.